Comparison of VRD- and matched VCD/CyBorD-treated patients
| . | VRD (N = 34) . | CyBorD (N = 68) . |
|---|---|---|
| Age, median (range), y | 66.5 (46-84) | 64.5 (43-82) |
| Male/female, % | 68/32 | 61/39 |
| Organ involvement, % | ||
| Heart | 79 | 81.5 |
| Renal | 54.5 | 59 |
| Liver | 21 | 18.5 |
| PNS/ANS | 21 | 17 |
| Number of involved organs, median | 2 | 2 |
| Mayo stage 1/2/3A/3B, % | 12/53/15/21 | 13/52/24/11 |
| SBP ≤100 mmHg, % | 44 | 42 |
| dFLC, median (range) | 170 (6-7228) | 186 (4-4468) |
| BM PCs, median (range) | 15 (0-30) | 15 (0-30) |
| eGFR, median (range)/eGFR <30 mL/min/1.73 m2, n (%) | 65 (10-133)/8 (23.5) | 83 (10-143)/6 (9) |
| Renal stage 1/2/3 (within patients with renal involvement) | 11/50/39 | 13/50/37 |
| Proteinuria (g)/24 h, median (range) | 7.96 (1.4-18) | 7.7 (1-21) |
| ≥VGPR/PR/NR after 1 mo, % | 41/27/27 | 39/26/35 |
| ≥VGPR/PR/NR after 3 mo, % | 82/18/0 | 45/31/24 |
| ≥VGPR/PR/NR after 6 mo,* % | 92/8/0 | 61/39/ 0 |
| CR/VGPR/PR at best response (ITT population),** % | 32/50/7 | 24/21/25 |
| . | VRD (N = 34) . | CyBorD (N = 68) . |
|---|---|---|
| Age, median (range), y | 66.5 (46-84) | 64.5 (43-82) |
| Male/female, % | 68/32 | 61/39 |
| Organ involvement, % | ||
| Heart | 79 | 81.5 |
| Renal | 54.5 | 59 |
| Liver | 21 | 18.5 |
| PNS/ANS | 21 | 17 |
| Number of involved organs, median | 2 | 2 |
| Mayo stage 1/2/3A/3B, % | 12/53/15/21 | 13/52/24/11 |
| SBP ≤100 mmHg, % | 44 | 42 |
| dFLC, median (range) | 170 (6-7228) | 186 (4-4468) |
| BM PCs, median (range) | 15 (0-30) | 15 (0-30) |
| eGFR, median (range)/eGFR <30 mL/min/1.73 m2, n (%) | 65 (10-133)/8 (23.5) | 83 (10-143)/6 (9) |
| Renal stage 1/2/3 (within patients with renal involvement) | 11/50/39 | 13/50/37 |
| Proteinuria (g)/24 h, median (range) | 7.96 (1.4-18) | 7.7 (1-21) |
| ≥VGPR/PR/NR after 1 mo, % | 41/27/27 | 39/26/35 |
| ≥VGPR/PR/NR after 3 mo, % | 82/18/0 | 45/31/24 |
| ≥VGPR/PR/NR after 6 mo,* % | 92/8/0 | 61/39/ 0 |
| CR/VGPR/PR at best response (ITT population),** % | 32/50/7 | 24/21/25 |
The 2 groups were matched for Mayo stage and dFLC levels. There were no statistically significant differences in their baseline characteristics regarding demographics or disease features.
NR, no response; SBP, systolic blood pressure.
P = .048; **P = .088.